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Simple Summary: It is a long-held notion that loss-of-function mutations in negative regulators of
the Hippo-YAP pathway, such as NF2, LATS1/2, have a similar potential to promote nuclear YAP
activity, which is thought to play an essential role in the pathogenesis of MPM. Whether loss-of-
function in these individual regulators uniformly affects the Hippo-YAP activity and contributes
to a similar disease phenotype has not yet been revealed in MPM. Surprisingly and interestingly,
we found in this study that loss-of-function in the upstream regulator NF2 of the Hippo pathway is
linked to the aberrant activation of Hippo-YAP-independent signaling. More importantly, our work
showed NF2 loss-of-function and dysregulated Hippo-YAP pathway define distinct MPM subsets
that differ in molecular features, therapeutic implications, patients’ prognosis, and in particular,
infiltrative immune signatures. Our findings in this study may be instrumental for the precise
management of immunotherapy and/or targeted therapy for MPM patients.
Abstract: (1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the
pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling
pathway. However, NF2 has functions beyond regulation of the Hippo pathway, raising the possibility
that NF2 contributes to MPM via Hippo-independent mechanisms. (2) We performed weighted gene
co-expression analysis (WGCNA) in transcriptomic and proteomic datasets obtained from The Cancer
Gene Atlas (TCGA) MPM cohort to identify clusters of co-expressed genes highly correlated with
NF2 and phospho (p)-YAP protein, surrogate markers of active Hippo signaling and YAP inactivation.
The potential targets are experimentally validated using a cell viability assay. (3) MPM tumors with
NF2 loss-of-function are not associated with changes in p-YAP level nor YAP/TAZ activity score, but
are characterized by a deficient B-cell receptor (BCR) signaling pathway. Conversely, MPM tumors
with YAP activation display exhausted CD8 T-cell-mediated immunity together with significantly
upregulated PD-L1, which is validated in an independent MPM cohort, suggesting a potential benefit
of immune-checkpoint inhibitors (ICI) in this patient subset. In support of this, mutations in core
Hippo signaling components including LATS2, but not NF2, are independently associated with better
overall survival in response to ICI in patients. Additionally, based on cancer cell line models, we
show that MPM cells with a high Hippo-YAP activity are particularly sensitive to inhibitors of BCR-
ABL/SRC, stratifying a unique MPM patient subset that may benefit from BCR-ABL/SRC therapies.
Furthermore, we observe that NF2 physically interacts with a considerable number of proteins that
are not involved in the canonical Hippo-YAP pathway, providing a possible explanation for its
Hippo-independent role in MPM. Finally, survival analyses show that YAP/TAZ scores together with
p-YAP protein level, but not NF2, predict the prognosis of MPM patients. (4) NF2 loss-of-function and
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dysregulated Hippo-YAP pathway define distinct MPM subsets that differ in their molecular features
and prognosis, which has important clinical implications for precision oncology in MPM patients.
Keywords: mesothelioma; NF2; LATS2; YAP; Hippo pathway; targeted therapy; immunotherapy
1. Introduction
Malignant pleural mesothelioma (MPM) is a highly lethal cancer, predominantly
characterized by the inactivation of tumor suppressor genes (TSGs) [1,2]. Large-scale
cancer genome sequencing of human MPM samples reveals that TSG genes involved in the
Hippo signaling pathway are mutated at a high frequency [3–5].
The core components of the Hippo signaling pathway include MST1 (mammalian
STE20-like protein kinase 1) and MST2, large tumor suppressor kinase 1/2 (LATS1/2),
and two adaptor proteins SAV1 (Salvador homolog 1), MOB1A/B (MOB kinase activator
1A/B) [6]. Hippo signaling converges on the LATS1/2-dependent phosphorylation of
the transcriptional master YAP (Yes-associated protein, encoded by YAP1). LATS kinase-
mediated phosphorylation at multiple sites (e.g., Ser127, Ser109) leads to sequestration
within the cytoplasm due to 14-3-3 protein binding followed by ubiquitin-mediated pro-
teolysis, negatively regulating YAP transcriptional activity. Following inactivation of the
Hippo pathway, unphosphorylated YAP and its co-activator TAZ translocate to the nucleus
and bind to TEAD1–4 transcription factors to control the expression of their target genes,
which have been shown to control cell proliferation and inhibit cell death, underpinning
the tumorigenic potential of YAP/TAZ. The core kinase Hippo pathway components are
regulated by numerous upstream proteins, e.g., neurofibromin 2 (NF2), TAOKs and KIBRA,
thereby linking the Hippo pathway to multiple aspects of cancer, such as cell size and pro-
liferation, tissue regeneration, immunity, metabolism, epithelial-to-mesenchymal transition
(EMT), and cancer therapy resistance and metastasis [7]. Of note, loss-of-function muta-
tions in NF2 and LATS1/2 have been frequently observed, accounting for approximately
50% of MPM cases [3,4]. In addition, inactivation of the Hippo pathway can also result
from non-mutational events, such as post-translational modifications [8].
We have recently systematically analyzed the potential therapeutic targets associated
with genetic alterations affecting the major TSGs in MPM [3], which suggests that two
well-characterized upstream components of the Hippo pathway NF2 and LATS1/2 that
negatively regulate YAP activity [9], may have different roles in MPM. Despite the high
prevalence of the dysregulated Hippo pathway in MPM, the role of these individual
components in disease pathogenesis is not completely understood. In addition, it remains
unclear whether NF2, the upstream regulator, mainly functions through the canonical
Hippo-YAP pathway or confers additional molecular rewiring during the development
of MPM.
In this study, we implemented weighted gene co-expression network analysis
(WGCNA) [10], a robust algorithm to uncover molecular rewiring correlated with pheno-
typic/genotypic traits of interest, to identify biologically meaningful clusters (modules)
of interconnected genes highly correlated with NF2 and p-YAP protein level, a surrogate
marker of YAP inactivation and active Hippo signaling, in MPM patients. WGCNA was
performed in proteomic datasets that are usually of higher reliability than transcriptomics
in reflecting signaling activity mediated by the pathway of interest obtained from The
Cancer Gene Atlas (TCGA) MPM cohort. We found different molecular signatures, par-
ticularly involving the tumor immune microenvironment and therapeutic vulnerabilities
specifically associated with NF2 deficiency and canonical Hippo-YAP pathway dysreg-
ulation. Our results revealed previously underappreciated roles of NF2 independent of
canonical Hippo-YAP signaling pathway, different immune infiltrates specific to NF2 and
Hippo-YAP signaling, and more importantly, supported further stratification of patients
with MPM based on dysregulation of NF2 and Hippo-YAP.
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2. Results
2.1. Molecular Clusters Correlated with NF2 and p-YAP Protein Levels in Clinical MPM Samples
Studies have suggested that NF2 suppresses tumorigenesis by activating core com-
ponents of the Hippo pathway (Figure 1A) [11–13]. NF2 is frequently mutated in clinical
MPM specimens (Figure 1B) and NF2 loss-of-function plays a key role in the pathogen-
esis of MPM [11,14]. To further explore this, we integrated the Reverse Phase Protein
Array (RPPA) data (containing 220 proteins) from the TCGA cohort of MPM patients
(N = 61; https://tcpaportal.org/tcpa/ accessed on 21 December 2020), which, as expected,
showed that genetic alterations of NF2 results in a significant decrease in NF2 protein
levels (Figure 1C). Despite this, the NF2 mutation is not associated with altered expression
of phospho (p)-YAP (S127) (Figure 1D), a well-established surrogate marker indicative
of the activity of the Hippo signaling pathway. Along these same lines, we did not ob-
serve a correlation between NF2 and p-YAP (S127) at the protein level (Figure 1E). These
results suggest that the genetic alteration of NF2 does not significantly affect the canonical
Hippo-YAP pathway in MPM. In contrast, genetic alterations of LATS2, a core component
of the Hippo pathway, caused a significant downregulation of p-YAP (S127), indicating
compromised Hippo signaling induced by LATS2 loss-of-function (Figure 1F). Further, we
utilized a previously curated YAP-TAZ gene signature that integrated target genes specific
to the YAP-TAZ pathway [15], which demonstrated that p-YAP (S127), but not NF2, was
significantly correlated with the YAP-TAZ score (Figure 1G). Taken together, our analysis
showed that, unlike LATS2, NF2 might play additional roles, independent of the canonical
Hippo-YAP pathway in the complex pathogenesis of MPM.
Of note, previous evidence demonstrated that Hippo-YAP activity could be regulated
by other signaling pathways beyond the LATS1/2 core cassette [16], and non-mutational
mechanisms could contribute to a deficient NF2 and core Hippo-YAP pathway [8,17].
We also observed high heterogeneity of NF2 protein levels in NF2-wild-type samples
(Figure 1C), and of DNA methylation in NF2, LATS1/2, and YAP1 across MPM tumors
(Figure S1A). As such, proteomic data (e.g., NF2, p-YAP) may more reliably reflect signaling
pathway (e.g., NF2, canonical Hippo) activity compared with transcriptomics and genetic
alterations. Thus, we utilized protein levels of NF2 and p-YAP to reflect the functional
activity of the corresponding pathways.
To uncover molecular features associated with NF2 and canonical Hippo-YAP pathway
in MPM, we applied weighted gene co-expression network analysis (WGCNA) [9,10], an
algorithm to cluster molecular aberrations that correlate with NF2 protein and p-YAP (S127),
to the RPPA and whole-genome transcriptomic data of the TCGA MPM cohort (Figure 1H,I).
The correlation analysis revealed 13 molecular modules or clusters of genes color-coded
according to the convention of WGCNA that are positively or negatively correlated with
NF2 or p-YAP (S127) (Figure 1I). Notably, genes in the positively correlated modules
indicate their abundance (co-expression) with respect to NF2- and p-YAP-represented
samples, while the negatively correlated ones signify attenuation of the network of genes.
Genes in the gray module are unable to be clustered [9]. The dysregulated molecular
modules specific to NF2 and canonical Hippo-YAP revealed by robust WGCNA would
provide valuable information on their individual roles in the pathogenesis of MPM.
2.2. NF2 Loss-of-Function Is Characterized by a Deficient B-Cell Receptor (BCR)
Signaling Pathway
The correlation network identified three significant modules/clusters that were all
positively correlated with NF2 protein levels (Figure 1I), meaning that the expression of the
genes in the three modules is low in MPM samples with an NF2 defect. The most correlated
module is the greenyellow module, containing 482 genes (correlation coefficient Pearson’s
r = 0.39; p-value = 0.004), followed by the pink (351 genes; r = 0.35; p-value = 0.001), and
the blue (742 genes; r = 0.32; p-value = 0.02). Pathway analyses (GO, KEGG, Reactome)
revealed that the genes enriched in the greenyellow module are mainly involved in several
pathways, e.g., MAPK signaling, proinflammatory signaling (Figure S2A).
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Figure 1. Weighted gene correlation network analysis (WGCNA) reveals gene modules or clusters correlated with NF2
and p-YAP in MPM. (A) Schematic representation showing key signaling molecules regulating Hippo pathway and YAP
activity. NF2 and other proteins function upstream and facilitate the activation of MST1/2, and then activate LATS1/2,
which causes inhibitory phosphorylation of YAP. Hypo-phosphorylated YAP translocates to the nucleus and recruits TEAD
transcription factors that regulate various biological processes. MST1/2-LATS1/2 complex acts as a core component of the
Hippo signaling pathway. (B) Genetic alterations of Hippo pathway components (NF2, LATS1/2) in TCGA (The Cancer
Genome Atlas) malignant pleural mesothelioma (MPM). (C,D) The protein level of NF2 and phospho (p)-YAP (S217) in
MPM tumors with mutated (mut) and wild-type (WT) NF2. (E) The correlation between NF2 and p-YAP (S217) at the
protein level in TCGA MPM. (F) The protein level of p-YAP (S217) in MPM tumors with mutated (mut) and wild-type
(WT) LATS2. Note that the protein quantification of LATS2 is not provided in the Reverse Phase Protein Array (RPPA)
dataset. (G) The correlation between YAP/TAZ score and p-YAP (S217) at the protein level in TCGA MPM. (H,I) WGCNA
analysis. In (H) the upper panel shows the sample dendrogram and trait heatmap. The middle panel shows a histogram of
network connectivity and the right is a log–log plot of the same histogram. The lower panel shows the gene dendrogram
obtained by average linkage with hierarchical clustering. The color row underneath the dendrogram shows the module
assignment determined by the Dynamic Tree Cut. Gray genes are unassigned to a module. Gene expression similarity is
determined using a pair-wise weighted correlation metric, and clustered according to a topological overlap metric into
modules. (I) Consensus network modules correlated with NF2 and p-YAP protein levels in MPM using the eigenmodule
(the first principal component of the module). Pearson correlation coefficient along with p-value in parenthesis underneath;
color-coded according to correlation coefficient (legend at right). The blue color indicates a negative correlation, while
the red represents a positive correlation. WGCNA analysis of gene expression generated by unsupervised hierarchical
clustering on the basis of topographical overlap followed by branch cutting reveals 13 network modules coded by different
colors. Genes in the positively correlated modules (in red) indicate the abundance of these genes conferred by individual
genetic events, while those in the negatively correlated ones (in blue) indicate the attenuation. Genes in the gray module are
those that cannot be clustered.
Intriguingly, the pink module was significantly enriched for genes of the BCR sig-
naling pathway, indicating a potential loss of antibody-mediated humoral immunity in
NF2-deficient MPM (Figure 2A–C). In addition, we analyzed the intramodular connectivity,
given that highly connected genes within a single module may serve as the hub with
core regulatory roles. The top 30 most connected genes in the pink module (ranked by
connection degree (from high to low)) were: CD79A, CD19, FCRL5, MGC29506, CD27,
KIAA0125, CD79B, ADAM6, TNFRSF17, MS4A1, FCRLA, PNOC, LOC96610, POU2AF1,
LAX1, C8orf80, BLK, CPNE5, CXCR5, CNR2, TNFRSF13B, FCRL1, IRF4, FLJ40330, CLEC17A,
FCRL3, MEI1, DERL3, FAM129C, and SPIB (Figure 2D). Among these hub genes, POU2AF1
is a transcriptional coactivator that is essential for the response of B-cells to antigens and
is required for the formation of germinal centers. The transcription factor SPIB binds to
the PU-box, a purine-rich DNA sequence acting as a lymphoid-specific enhancer [18,19].
Genes in the blue module were enriched in a stromal signature, e.g., angiogenesis, extra-
cellular matrix organization, extracellular ligand-receptor interaction, and mesenchymal
signature (Figure S2B), suggesting that MPM patients with NF2 loss-of-function might
not be responsive to anti-angiogenic therapies, which have shown a highly heterogeneous
effect in unselected MPM patients [20,21].
Given that our above WGCNA analysis revealed a potential loss of antibody-mediated
humoral immunity in NF2-defective MPM (Figure 2A–C). We further analyzed the correla-
tion between gene expression of CD20 (also known as MS4A1), a B-lymphocyte-specific
membrane protein [22,23], and NF2 across TCGA MPM samples, demonstrating a signifi-
cantly positive correlation pattern (Figure 2E). Recent evidence highlighted the previously
underappreciated role of intra-tumoral B-cells in predicting patients’ prognosis and me-
diating therapeutic responses to immune checkpoint blockade (ICB) treatment [24,25].
Interestingly, we observed that in MPM with low NF2 expression, a high plasma B-cell
infiltrative signature predicts better overall survival (Figure 2F).
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Figure 2. NF2 loss-of-function is characterized by a deficient B-cell receptor (BCR) signaling pathway. (A–C) The top 5
significantly enriched Gene Ontology (GO; biological process (BP)), Kyoto Encyclopedia of Genes and Genomes (KEGG) (B),
and Reactome (C) pathways based on genes in the MEpink module. Cnetplot in (C, lower panel) list genes in the enriched
Reactome pathways. (D) STRING (https://string-db.org/ accessed on 21 December 2020) protein interaction map based on
the top 30 hub genes in the MEpink module. (E) Correlation (Pearson r) between gene expression of CD20 (also known as
MS4A1), a B-lymphocyte-specific membrane protein, and NF2 across TCGA MPM coho t. (F) Kaplan–Meier curves for
MPM patients grouped by the plasma B-cell infiltrative signature and NF2 gene ex ression. The high vs. low groups are
based on the median value of the indicated gene expression. Here, multiple covariates, e.g., tumor stage and purity, patients’
age and gender were included for adjustment. (G) Volcano plot showing the correlation between the AUC (Area the Under
Curve) value of drugs and the NF2 protein level. Blue dots indicate the significantly (p-value < 0.05) negatively correlated
drugs while the red indicates the positively correlated ones. Here, a positive correlation indicates the association of a larger
(more resistant) AUC value with higher gene expression and vice versa.
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Concerning the potential therapeutic targets associated with NF2 loss-of-function
in tumors, we correlated the protein level of NF2 with the drug sensitivity profiles
across a panel of solid cancer cells based on the publicly available GDSC dataset (https:
//www.cancerrxgene.org/, accessed on 21 December 2020). Our analysis revealed that
cancer cells with decreased NF2 expression display high sensitivity to DNA synthesis
inhibition (Cytarabine, Oxaliplatin, and 5-Fluorouracil) [26] and epidermal growth fac-
tor receptor (EGFR) targeted therapies (Gefitinib and Lapatinib) [27–29] (Figure 2G). In
support of this, previous evidence showed that NF2 negatively regulated EGFR signaling
by restraining the EGFR into a membrane compartment, preventing the signaling trans-
duction or internalization of EGFR. In confluent Nf2 −/− cells, EGFR activation persists,
driving continued proliferation that is halted by specific EGFR inhibitors [27]. Whether the
sensitivity to EGFR-targeted therapies is observed in immune-competent in vivo models
or clinical settings awaits further investigation.
2.3. MPM Tumors with Lower p-YAP Level Display an Exhausted T-Cell-Mediated
Immune Phenotype
In view of the role of the canonical Hippo pathway in MPM, we observed that the
inactive form of YAP, p-YAP (S127), was positively correlated with the turquoise module
(1084 genes; r = 0.48; p-value = 2 × 10−4), but negatively with the green (482 genes;
r = −0.39; p-value = 0.003), followed by the red (476 genes; r = −0.39; p-value = 0.004)
(Figure 1I). Genes in the turquoise module are mainly enriched for the neuronal system,
keratinization, the formation of the cornified envelope, and EGFR signaling pathways
(Figure S3A), suggesting a reduced expression of these genes in MPM samples with YAP
activation. Of note, the latter three signaling pathways are mainly related to the epithelial
phenotype, which was in agreement with previous reports demonstrating that YAP is
a critical mediator of the EMT process and mediates the resistance to EGFR-targeted
therapies [30,31].
Genes in the negatively correlated green module are predominantly involved in cell
division, particularly mitosis (Figure S3B), suggesting a high tumor proliferation activity in
MPM with YAP activation that is consistent with the canonical roles of the Hippo-YAP path-
way in regulating cell size and proliferation [32]. Thus, inhibitors (e.g., AURKB/AURKA
inhibitor; Figure S3B) targeting the mitotic phase may be promising for this MPM subset, as
direct targeting of YAP is highly toxic and there are no clinically approved specific inhibitor
directly blocking YAP signaling [33]. Previous evidence also reveals the importance of
targeting AURKB/AURKA in cancer cells with activated YAP [34,35].
Of particular interest, genes in the negatively correlated red module were mostly
enriched in T-cell-mediated adaptive immune responses (Figure 3A,B). The top 30 most
connected genes in the red module (ranked by connection degree (from high to low))
were: LCK, CD3E, SH2D1A, CD6, CD3D, SIRPG, CD2, SLAMF6, IL2RG, CD247, TBC1D10C,
TRAT1, SIT1, ZAP70, CXCR3, SLA2, ITGAL, CD5, GZMK, TIGIT, CD96, ZNF831, ITK,
THEMIS, PYHIN1, P2RY10, ACAP1, CXCR6, CD27, GPR171. Among these, TIGIT rep-
resents an immune checkpoint T-cell immunoreceptor overexpressed by T-cells with an
exhausted phenotype and functions via suppressing T-cell activation by promoting the
generation of mature immunoregulatory dendritic cells, and its inhibitors have shown
promises in clinical trials [36]. Additionally, we observed a significant negative correlation
between PD-L1 and p-YAP at the protein level in MPM, and LATS1/2-mutant MPM tumors
were associated with higher PD-L1 expression (Figure 3C). These data indicate that a mix
of activated and exhausted T-cells in MPM samples are associated with activated YAP
signaling. In contrast, there was no correlation between PD-L1 and NF2 at the protein level
and also no significant difference in the PD-L1 protein level between MPM tumors with
mutated and wild-type NF2 (Figure 3D). These results further support the differential roles
of NF2 and Hippo pathways in the pathogenesis of MPM. Indeed, a retrospective analysis
of patients receiving ICB [37] demonstrated that mutations of LATS1/2, rather than of NF2,
predict better overall survival, which was even more evident after incorporating MST1
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and YAP1 mutations (Figure 3E). Collectively, these data highlight the importance of ICB
treatment for a subset of MPM patients with an inactivated Hippo pathway.
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Figure 3. MPM tumors with YAP activation display exhaustion of T-cell-mediated immune response. (A,B) The top 10
significantly enriched Gene Ontology (GO; biological process [BP]) (A) and Reactome (B) pathways based on genes in
the MEred module. (C,D) Correlation (Pearson r) between PD-L1 protein and p-YAP (C, left) or between PD-L1 protein
and NF2 protein (D, left). Violin plots show the association between PD-L1 and the genetic alterations of LATS2 (C, right)
or NF2 (D, right). (E) Association between the mutations in LATS1/2 (n = 92) or other key regulatory components
(LATS1/2, MST1, YAP1; n = 111) of the Hippo pathway with overall survival in cancer patients after immune checkpoint
blockade (anti-PD-1/PD-L1, or anti-CTLA4, or combination treatment). Of note, there is no significant difference in the
treatment regimens between the wildtype (WT) and mutated (Mut) subgroups. Data were downloaded from cBioPortal
https://www.cbioportal.org/ accessed on 21 December 2020. (F,G) Volcano plots showing the proteins (F) and drugs (G)
that are correlated with p-YAP across TCGA MPM samples and solid cancer cell lines, respectively. Blue dots indicate the
significantly (p-value < 0.05) negatively correlated proteins/drugs while the red the positively correlated ones. In (G) the
AUC (Area Under Curve), value of drugs was used to indicate the drug effect, with a positive correlation representing the
association of a larger AUC value (more resistance) with a higher p-YAP level and vice versa. (H) The median inhibitory
concentration (IC50) values of a panel of MPM cell lines were treated with Dasatinib (96 h). MPM cells seeded in triplicate
at 96-well plates were drugged 24 h later, over a 12-point concentration range (two-fold dilution). DMSO-treated cells were
used as control. IC50 was determined using GraphPad Prism 7. N = 3 biological replicates. The lower panel shows the gene
annotations of the indicated MPM cell lines.
Besides, we sought to know whether the correlation between YAP activity and PD-
L1 expression is specific to MPM tumors. Based on the TCGA Pan-cancer cohort, we
observed that the correlation pattern between YAP activity (reflected by curated YAP/TAZ
downstream target score) and PD-L1 expression displays the highest in MPM (Figure S4A),
suggesting that tumor-derived microenvironment may play a role in regulating PD-L1
in addition to YAP signaling. Supporting this notion, MPM tumors display the highest
YAP/TAZ downstream target score across different cancer types (Figure S4B).
In addition, at the protein level, we identified Cyclin B1, a key regulator of the cell
cycle at the G2/M (mitosis) transition, as the most negatively correlated protein with p-YAP
(S217), which is in agreement with the aforementioned green module that is predominantly
involved in the mitotic process (Figure 3F). Moreover, we integrated the drug sensitivity
profile (indicated by Area Under the Curve (AUC), higher AUC suggests more resistance)
and proteomic data across hundreds of solid cancer cell lines, demonstrating that cells
with high YAP activity (reflected by low p-YAP) are most sensitive to Nilotinib, a clinically
approved BCR-ABL/SRC inhibitor (Figure 3G). To test this, we treated a panel of MPM cells
with Dasatinib, another clinically approved inhibitor selectively targeting BCR-ABL and
SRC, which showed that MPM cells with LATS1/2-mutation are most sensitive to Dasatinib
(Figure 3H), as MPM tumors with LATS1/2 mutations were associated with significantly
higher YAP (Figure 1F). Immunoblot data showed that LATS1/2 mutations did not result
in loss of protein expression (Figure S5), which was in line with a previous study by
Miyanaga et al. [38] This observation might be because mutated LATS1/2 affects its kinase
function but not the protein level, or because there exists some other molecular aberrations
that affect the Hippo-YAP signaling pathway in these cell lines. For instance, MESO-211H
cell line harbors LATS2 mutation but not LATS1; however, evidence shows the presence
of fusion transcripts of LATS1 in MESO-211H, which leads to its functional loss [38].
Interestingly, preclinical and clinical evidence demonstrated that BCR-ABL/SRC inhibitors
enhance the cytotoxic effects of T-cells and the efficacy of ICBs [9,39,40], suggesting that
BCR-ABL/SRC inhibitors not only target the cancer cells but also modulate the tumor
immune microenvironment. Notably, Met5A, which has been widely used as a normal
mesothelial cell line, also exhibits a certain responsiveness to Dasatinib. This might result
from the effect of the integrated SV40 Tag in Met5A cells [41], in that SV40Tag is one of the
most potent carcinogens, and is known to cause massive aneuploidy due to its perturbation
of the retinoblastoma (pRb) and p53 tumor suppressor proteins [42].
Notably, four highly selective AKT inhibitors (Uprosertib, AZD5363, Afuresertib,
MK-2206) were also listed as potential sensitive inhibitors (Figure 3G). This observation
was in line with the protein correlation data showing that increased YAP activity (lower
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p-YAP) is positively correlated with enhanced AKT signaling pathway, which is reflected
by a high level of eIF4G (positive correlation), a key downstream effector of AKT/mTOR,
and a low level of p-RICTOR (negative correlation), a well-established negative upstream
regulator of AKT/mTOR (Figure 3F). In support of this, YAP has been shown to mediate the
crosstalk between the Hippo and PI3K–AKT–mTOR pathway in organogenesis [43]. These
data suggest that cancer cells with activated Hippo-YAP signaling may be more sensitive
to AKT-targeted therapy. Given the potential roles of YAP in immunity, AKT inhibition
would likely improve the sensitivity of tumors to the host immune system resulting from
activated YAP signaling. Supporting this notion, targeting the PI3K-AKT-mTOR pathway
has been shown to modulate the immunosuppressive microenvironment, enhancing the
sensitivity to tumor-specific CD8+ T-cell-mediated cytotoxicity, and augmenting the effect
of immunotherapy [44,45].
2.4. Dysregulation of NF2 and Hippo-YAP Exhibits Different Infiltrative Immune Signatures
in MPM
Given the dysregulated immune profiles described above, we performed a systematic
analysis of immune infiltrates across TCGA pan-cancer cohort (n = 28) in the context of
mutated NF2 and LATS1/2, based on the TIMER algorithm that provides information
regarding immune cell types and their abundance by multiple immune deconvolution
methods [46]. Our analysis revealed tumor-infiltrating CD8+ T-cells, particularly CD8+
effector memory T-cells, were mainly enriched in MPM harboring LATS1/2 mutation,
compared with NF2-mutant MPM and other cancer types (Figure 4A). We also provided
evidence that a T-cell regulatory (Tregs) signature was enriched in LATS1/2-mutant MPM
(Figure 4A). These data were in agreement with the above WGCNA analysis showing the
presence of a mixed population of activated and exhausted T-cells related to Hippo-YAP
aberration (Figure 3). Regarding B-cell infiltrates, which have been shown to play a role in
promoting the anti-tumor immune response [24,47], interestingly, MPM tumors harboring
LATS1/2 rather than NF2 display enriched plasma B-cell signature (Figure S6). Furthermore,
we investigated the distribution of immune subtype models (C1–C6) across the TCGA
MPM cohort [48]. Comparing the immune subtypes in low versus high protein levels
of NF2 and p-YAP showed that low levels of NF2 and p-YAP are consistently associated
with a lower Inflammatory (Immune C3) and higher Lymphocyte Depleted (Immune C4)
signature, whereas having opposite patterns in other immune subtype signatures, such
as IFN−gamma Dominant (Immune C2), TGF−beta Dominant (Immune C6), Wound
Healing (Immune C1) (Figure 4B). Consistently, based on an independent MPM dataset
(GSE29354) [49], we observed that the hub genes-based signature score in the red module
(Figure 1I) is significantly positively correlated with YAP/TAZ target score but not NF2
gene expression (Figure 4C). Collectively, these data suggest that NF2 and p-YAP have
divergent immune signatures, further supporting that NF2 has functions independent of
classical Hippo-YAP signaling.
PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability
(MSI) represent well-characterized biomarkers predicting the responsiveness to ICB treat-
ment [50]. Notably, MPM samples display very low TMB and MSI compared with other
solid cancer types (Figure 5A,B). Since the mutational status of LATS1/2 is associated
with high PD-L1 expression (Figure 2C) and predicts better responsiveness to ICB treat-
ment (Figure 2E), we next sought to know whether LATS1/2 mutations are related to high
TMB/MSI status. Interestingly, we observed that LATS1/2 mutations did not associate
with differential TMB/MSI status compared with the WT counterparts (Figure 5C), which
is in line with recent evidence demonstrating that the value of TMB in predicting the
responsiveness to ICB treatment is independent of PD-L1 expression [51].
Collectively, these analyses suggested that different tumor-infiltrating immune cell
patterns exist between dysregulation of NF2 and Hippo-YAP signaling in MPM.
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Figure 4. Dysregulation of NF2 and Hippo-YAP exhibits different infiltrative immune signatures in MPM. (A) Tumor-
infiltrating immune cell profiles across the TCGA pan-cancer cohort were shown. The number of patients shown in
parentheses. Data were downloaded from TIMER (version 2.0), a comprehensive resource for systematic analysis of immune
infiltrates across diverse cancer types (http://timer.comp-genomics.org/ accessed on 21 December 2020) (See the methods).
(B) Percentage of immune subtype models (C1–C6) across the TCGA MPM cohort, in which the reverse-phase protein
array (RPPA) data were used. The genes contained in each signature were evaluated using model-based clustering by p
the “mclust” R package. Each sample was finally to be grouped based on its predominance with the C1–C6 signature. The
immune subtype models were based on Thorsson V et al. Immunity. 2018 (See the methods). (C) Correlative analysis of the
hub genes-based signature score in the red module (Figure 1I) with YAP/TAZ target score and NF2 gene expression based
on an independent MPM dataset (GSE29354).
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Figure 5. Association of LATS1/2 mutations with TMB and MSI in MPM. (A,B) Tumor mutational bur-
den (TMB; A) and microsatellite instability (MSI; B) across TCGA pan-cancer cohort. (C) Association
of LATS1/2 mutations with TMB and MSI in MPM.
2.5. NF2 and Hippo-YAP Engage Different Protein Interactors and Are Differentially Associated
with Patient Prognosis
Our data revealed differential roles of NF2 and YAP signaling in the pathogenesis
of MPM, as indicated by different molecular signatures, drug sensitivity and immune
profiles, indicating that NF2 may act through mechanisms independent of Hippo-YAP. We
hypothesized that NF2 might interact with additional signaling pathways independent
of the canonical Hippo-YAP. To test this, we integrated three publicly curated databases
of protein physical interactions (BioGRID; HitPredict; APID) (Figure 6A), which showed
that the common proteins physically interacting with NF2 are mainly enriched in DNA
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repair and cell cycle beside the Hippo pathway (Figure 6B–D and Figure S7). Of note, the
aforementioned EGFR family members (EGFR, ERBB2) were also represented (Figure S7).
Furthermore, we mined a dataset (GSE48078) [52] in which Yap1 overexpression and Nf2
knockout were performed on the same mammalian brain cells, respectively (Figure 6E),
demonstrating a difference in gene expression changes (adjusted p-value < 0.05) resulting
from Yap overexpression compared with Nf2 deletion. Clinically, univariate and multivari-
ate survival analysis showed that YAP/TAZ score and the protein level of p-YAP but not
NF2 were prognostic in MPM patients (Figure 6F,G).
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Figure 6. A pleiotropic role of NF2. (A) The common (N = 93) physical interactors of NF2 based on 3 curated public
databases (BioGRID, HitPredict, and APID). (B–D) Top 10 significantly enriched Reactome (B), Kyoto Encyclopedia of
Genes and Genomes (KEGG) (C), and Gene Ontology (GO; biological process [BP]) (D) pathways based on the common
interactors (N = 93) of NF2 in (A). (E) Venn plot showing the gene changes in mouse brain cells with Yap1 overexpression
and Nf2 knockout. Data were downloaded from GSE48078. (F) Association of NF2, phospho-YAP (S127), YAP/TAZ score
with overall survival in MPM patients. (G) Univariate (A) and multivariate (B) survival analysis showing that YAP/TAZ
score and the protein level of p-YAP (S127) but not NF2 predict prognosis of MPM patients.
Together, these data supported the notion that NF2 is engaged in additional signaling
pathways beyond Hippo-YAP, which might explain the differential roles of NF2 and Hippo-
YAP in the pathogenesis of MPM.
3. Discussion
It is a long-held notion that loss-of-function mutations in negative regulators of the
Hippo pathway, such as NF2, LATS1/2, have a similar potential to promote nuclear
YAP activity [11,53–55]. Genetic alterations of NF2 and LATS1/2 have been observed
particularly in MPM, as well as tumors arising from the nervous system [4,11,12]. Evidence
shows that the presence of nuclear YAP is strongly associated with mutations in NF2
in sporadic tumors that derive from the nervous system, such as schwannomas and
meningiomas [12,56]. However, whether loss-of-function in these individual regulators
uniformly affects the Hippo-YAP activity and contributes to a similar disease phenotype
has not yet been revealed in MPM, in which Hippo pathway deregulation is frequent and
thought to be critical for the pathogenesis of MPM [11]. Surprisingly and interestingly,
we found in this study that loss-of-function in the core component LATS2, rather than the
upstream regulator NF2 of the Hippo pathway, is linked to the aberrant activation of Hippo-
YAP signaling. Integrated analysis of proteomic and transcriptomic datasets uncovered
different modules/clusters associated with NF2 and p-YAP. More importantly, our findings
revealed potentially targeted- or immune-therapies for MPM subsets associated with
Hippo-YAP dysregulation.
3.1. A Pleiotropic Role of NF2
NF2 is one of the most frequently mutated genes regulating the Hippo pathway
in MPM [14]. NF2 has been shown to regulate signaling pathways other than Hippo,
such as EGFR-RAS-ERK, and mediate signaling events between the actin cytoskeleton
and the plasma membrane [11,13]. These observations raise the question to what extent
NF2-mediated tumor suppression is mediated by the Hippo-dependent modulation of
YAP/TAZ activity and the possibility that dysregulation of Hippo-independent functions
of NF2 also contributes to mesothelioma development.
In this study, we showed that genetic alterations of NF2, despite decreasing the
NF2 protein level, is not associated with altered expression of p-YAP. Furthermore, there
is no correlation between NF2 and p-YAP. Pathway analyses (GO, KEGG, Reactome)
revealed that the molecular clusters correlated with NF2 protein level are involved in
multiple biological processes, such as MAPK, interleukin, and inflammatory signaling
pathways. Additionally, the proteins physically interacting with NF2 are enriched in
multiple pathways including Hippo. These results support the notion that NF2 has other
functions beyond the canonical Hippo-YAP pathway in the development of MPM [11,13].
Intriguingly, we showed that solid cancer cell lines with NF2 loss-of-function may
benefit from EGFR-targeted therapy (Figure 2G), which is supported by a previous study
demonstrating that Nf2 deletion promotes EGFR activation, thereby rendering sensitivity
of Nf2-deficient cells to EGFR inhibitors [27]. The presence of activated EGFR signaling
has been reported in a subset of MPM, although the subset has not been specified [57–59],
arguing the need for biomarker-driven stratification for EGFR-targeted therapy in MPM.
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3.2. Hippo Pathway Dysregulation
Aberrant Hippo signaling pathway has been widely observed in clinical MPM sam-
ples [3,60]. In our study, LATS2 mutations, accounting for approximately 11% of MPM
and functioning as one of the core components of the Hippo pathway, is associated with
aberrant Hippo-YAP (Figure 1F). Of note, it has been reported that Hippo-YAP accounts for
more than 70% of clinical MPM samples [61], which can be explained by the intersection of
the Hippo signaling pathway with other pro-tumorigenic signaling pathways. The Hippo
pathway is engaged in multiple biological processes, such as cell size and proliferation, im-
munity, metabolism, cancer therapy resistance and metastasis [7]. Emerging evidence has
supported the role of canonical Hippo-YAP signaling in cancer immunity [62–65], which
was also revealed in MPM in our study. Of note, the CD8+ T-cell-related immune signature
is mostly dysregulated in MPM with the LATS1/2 mutation that leads to Hippo-YAP activa-
tion, compared with other cancer types (Figure 4A). Whether this link is tumor-specific
warrants further investigation.
A previous study showed that 5 out of 7 LATS2-mutant MPM also have co-mutated
NF2, and defined a unique subset of MPM with LATS2/NF2 co-occurring mutations [66].
Interestingly, single inactivation of either NF2 or LATS2 did not affect the proliferation of
MPM cells, which, however, could be effectively enhanced by co-mutations. Moreover,
based on their protein array data that contained phosphorylation levels of 40 proteins,
LATS2/NF2 co-occurring mutations displayed different molecular rewiring and thera-
peutic vulnerabilities compared to the single inactivation, suggesting different roles of
NF2 and LATS2 in MPM. However, they did not associate this genetic background with
immune infiltration.
3.3. Compromised Tumor Immunity in MPM
Immune checkpoint blockade (ICB) has shown promises in MPM, but is plagued with
low and heterogeneous response rates [67–69], suggesting that biomarker-guided stratifi-
cations of MPM subsets for immunotherapies are urgently needed [1]. In a recent study,
we have demonstrated that LATS1/2 mutational status may represent a useful biomarker
to stratify MPM patients for immunotherapy targeting the immune checkpoint proteins
PD1/PD-L1 [9]. Previous evidence also demonstrated that LATS1/LATS2 deletion in
tumors, which activates YAP signaling, induced increased tumor immunogenicity, leading
to tumor destruction by enhancing anti-tumor immune responses [62]. Moreover, the
YAP-driven subtype of small-cell lung cancer displays a highly enriched T-cell inflamed
signature [70]. Notably, in the study by Moroishi, T. et al. [9] demonstrating the role of
the LATS1/2 mutation in suppressing immunity in cancer, their findings were based on
three different murine syngeneic tumor models (B16, SCC7, and 4T1). However, in our
study, we observed the role of the LATS1/2 mutation in modulating cancer immunity
is the most prominent in human MPM compared with other cancer types (Figure 4A),
suggesting tissue-specific immunoregulation [71–73]. In this study, of particular interest,
we observed that aberrant NF2 and Hippo-YAP pathways are associated with different
patterns of dysregulation in adaptive immune responses. Specifically, NF2 loss-of-function
is correlated with compromised BCR-mediated immunity, whereas aberrant Hippo-YAP is
correlated with enriched T-cell-mediated immunity and plasma B-cell infiltrates. These
lines of evidence support ICB treatment for the MPM subset with an aberrant Hippo-YAP
signaling pathway. Additionally, in our study, we found exhausted adaptive immunity
accompanied by YAP activation, as shown by upregulated (Figure 3C,F) or positive correla-
tion with (Figure S4A) PD-L1 expression. In line with this, a recent study showed that the
Hippo pathway could upregulate PD-L1, thereby promoting immune evasion in human
cancer [74]. Together, the evidence above indicates that YAP signaling induces activated
and exhausted T-cells, both prioritizing anti-PD1/PD-L1 for this MPM subset.
Currently, biomarkers to predict a clinical response have largely focused on the T-
cell compartment. However, other immune subsets may also contribute to anti-tumor
immunity. Activated B-cells can release antibodies that tag tumor cells for attack by
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other cellular players of the immune system, e.g., enabling the T-cells to target tumor
cells effectively [75]. Recent studies have shown that B-cells are an essential element to
predict effective antitumor immune response [24,47], highlighting the potential role of
B-cells in coordinating the response, in part, to ICB treatment, with implications for the
development of biomarkers and therapeutic targets. In this study, importantly, we showed
that in MPM with low NF2 expression, a high plasma B-cell infiltrative signature predicts
longer survival than that of a low one (Figure 2F). In addition, the mechanism whereby
NF2 loss-of-function drives a deficient B-cell-mediated immunity remains unclear. Our
analysis provided some potential clues through the identification of hub genes that may
play a central regulatory role. Specifically, POU2AF1 and SPIB are transcription factors
that are essential for the response of B-cells to antigens [18,19]. In this case, there might
be a potential link among NF2, POU2AF1, and SPIB, which requires further investigation.
Together, our data provide potential insights into how B-cell-mediated immune response
work in the context of MPM development, which may be valuable in the design of vaccines
for the MPM subset with intact NF2.
3.4. Combined Targeted Therapy and Immunotherapy for an MPM Subset
Recently, several studies have demonstrated the potential of immunotherapies to treat
patients with mesothelioma [67,76,77]. Despite the promise, the majority of MPM patients
are unresponsive to monotherapy or dual immunotherapies. PD-L1 protein expression
on tumor or immune cells represents the first clinically approved predictive biomarker
for the benefit of ICB treatment. In our study, we found that Hippo-YAP activity is
significantly correlated with PD-L1 expression in MPM samples, supporting anti-PD/PD-
L1 immunotherapy for this subset of MPM patients. More intriguingly, we found that
mutations affecting the core signaling molecules (LATS1/2, MST1) regulating Hippo-YAP
activity in MPM patients show better overall survival after ICB treatment.
There is a growing interest in the development of combined immunotherapy and
molecularly targeted therapies in fighting against cancer [78–80]. In the setting of MPM,
how to optimize combination therapy remains a challenge. In this study, we found that
inhibitors selectively targeting BCR-ABL, such as Dasatinib, preferentially inhibit LATS1/2-
mutant MPM cells. More importantly, Dasatinib and other clinically approved BCR-ABL
inhibitors have been shown to enhance T-cell-mediated immune response in various can-
cer types [9,39,81], including MPM [81]. Based on multi-region whole-exome and T-cell
receptor (TCR) sequencing, Chen et al. [81] evaluated the evolution of T-cell repertoire het-
erogeneity of MPM under Dasatinib treatment, demonstrating a highly heterogeneous TCR
repertoire within MPM samples. Intriguingly, the evidence also showed that, compared to
pre-treatment tumors, Dasatinib treatment induced a significant increase in T-cell clonality,
and patients with higher T-cell clonality and more homogeneous T-cell repertoire after
treatment had significantly better survival. The findings by Chen and colleagues indicated
that Dasatinib might induce expansion and reactivation of T-cells, highlighting combined
ICB with Dasatinib as a promising new treatment for MPM. However, the study by Chen
et al. did not investigate their findings with Dasatinib in the context of genetic alterations
in MPM.
Collectively, the combination of BCR-ABL targeted therapies with ICB might enhance
the clinical utility of immunotherapy for MPM subsets with YAP activation. Additionally,
considering the association between NF2 loss-of-function and deficient BCR signaling and
the crucial role of B-cells in enhancing T-cell-mediated anti-cancer immunity [24,47], the
combination of intact NF2 with activated YAP signaling pathways may provide a better
stratification of MPM patients responsive to ICB.
3.5. Study Limitations
This study contains some limitations, e.g., the lack of experimental and cohort valida-
tions of the findings, and small sample size.
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4. Materials and Methods
4.1. WGCNA and Function Enrichment Analyses
To identify the gene expression profiling associated with the protein level of NF2 and p-
YAP (S127) in MPM, we applied the R package “WGCNA” to whole-genome transcriptomic
data of the TCGA MPM cohort. In WGCNA, genes are clustered based on the co-expression
patterns, then a gene co-expression network is constructed, which was transformed into the
adjacency matrix and then topological overlap matrix (TOM) [9,10]. Genes were grouped
into different modules (clusters) using the dynamic tree cut algorithm, according to the
TOM-based dissimilarity. The module eigengene (ME) was calculated based on the first
principal component of each module. The ME values were correlated (Pearson) with sample
traits defined by the protein level of NF2 and p-YAP (S127) in MPM samples. Here, we
set the soft-thresholding power at 12 (scale-free R2 = 0.9), cut height at 0.25, and minimal
module size to 30, to identify key modules. The module significantly correlated with
sample traits was selected to explore its biological functions, such as Gene Ontology (GO),
Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome pathway enrichment
analyses, using the R package “clusterprofiler” [82]. Hub genes were defined as the top 30
intramodular connected genes.
4.2. Cell Culture and Cell Viability Assay
Cell lines used in this study include: normal human mesothelial cells Met-5A (RRID:
CVCL_3749), MPM cell lines NCI-H28 (from ATCC (American Type Culture Collection,
Manassas, VA, USA); RRID: CVCL_1555), NCI-H2052 (from ATCC; RRID: CVCL_1518),
NCI-H2452 (from ATCC; RRID: CVCL_1553) [9,83], ACC-MESO-4 (from RIKEN Cell
Bank; RRID: CVCL_5114), ACC-MESO-1 (from RIKEN Cell Bank (Ibaraki, Japan); RRID:
CVCL_5113), MSTO-211H (DSMZ (German Collection of Microorganisms and Cell Cul-
tures, Brunswick, Germany); RRID: CVCL_1430) and JL-1 (DSMZ; RRID: CVCL_2080),
and primary MPM cells (BE261T, established from surgically resected MPM tumors). All
human cell lines have been authenticated using STR profiling within the last three years,
and are confirmed free from mycoplasma contamination (Microsynth, Bern, Switzerland).
Cells were cultured in RPMI-1640 medium with 10% fetal bovine serum and 1% peni-
cillin/streptomycin. The human study was performed under the auspices of protocols
approved by the institutional review board of Inselspital Bern (KEK number: 042/15), and
informed consent was obtained from patients.
Cells seeded in triplicate at 96-well plates (1000–1500 cells/well in the tissue-culture
treated plate (Corning, #353072)) were treated with the indicated drugs the next day,
over a 12-point concentration range (two-fold dilution), with DMSO as the vehicle. Cell
viability was determined 96 h post-treatment by the Acid Phosphatase Assay Kit (ab83367;
Abcam) [9,84]. The median inhibitory concentration (IC50) was calculated using GraphPad
Prism 8.
4.3. Immunoblots
Cell lysates were prepared using RIPA buffer (Cell Signaling Technology) containing
protease inhibitor cocktail and phosphatase inhibitors. Equal amounts of total proteins
were separated by SDS-PAGE (#4561033; Bio-Rad) and transferred to nitrocellulose mem-
branes (#170-4156; Bio-Rad). After brief incubation with blocking buffer (#927-4000; Li-COR
Biosciences, Bad Homburg, Germany) at room temperature, the membranes were blotted
with primary antibodies (LATS1 (Cell Signaling Technology, #9153S), LATS2 (Novus Bio-
logicals, #NBP3-03913), NF2, (Cell Signaling Technology, #6995S), beta-actin (Cell Signaling
Technology, #3700S)) and anti-rabbit (#926–32211) or anti-mouse (#926-68020) secondary
antibodies (Promega, Madison, WI, USA). Membrane-bound secondary antibodies were
visualized by the Odyssey Infrared Imaging System (Li-COR Biosciences).
Cancers 2021, 13, 1561 18 of 23
4.4. Public Databases
Transcriptomic (n = 87) and whole-genome exome sequencing data (n = 81) of MPM
samples were downloaded from TCGA (https://portal.gdc.cancer.gov/ accessed on
21 December 2020). The clinical characteristics of MPM patients were summarized in
Table S1. Normalized level 3 data of reverse phase protein array (RPPA) were down-
loaded from The Cancer Proteome Atlas (TCPA) database (https://tcpaportal.org/tcpa/
accessed on 21 December 2020) [85], which quantified 220 proteins in 61 out of the 87 MPM
samples in TCGA. Here, TCPA Level 3 data were utilized, and the proteomic data nor-
malization was processed as follows (For the details please refer to the FAQ section:
https://tcpaportal.org/mclp/# accessed on 21 December 2020): (1) Calculate the median
for each protein across all the samples. (2) Subtract the median (from step 1) from val-
ues within each protein. (3) Calculate the median for each sample across all proteins.
(4) Subtract the median (from step 3) from values within each sample.
Protein-interacting data were downloaded from Agile Protein Interactomes DataServer
(http://cicblade.dep.usal.es:8080/APID/init.action accessed on 21 December 2020), Bi-
oGRID (version 4.0; https://thebiogrid.org/ accessed on 21 December 2020), and Hit-
Predict (http://www.hitpredict.org/ accessed on 21 December 2020). The interaction
map among the interactors of NF2 was constructed and downloaded from STRING
(https://string-db.org/ accessed on 21 December 2020) [86]. Drug (n = 481) sensitivity
data across solid cancer cell lines (n = 659) were downloaded and reanalyzed from pub-
lished studies [87,88]. Fisher’s z-transformation was applied to the correlation coefficients
to adjust for (normalize) variations in cancer cell line numbers across small molecules
and cell lineages. Genetic and survival data of patients after immunotherapies (anti-
PD1/PDL1, anti-CTLA4) were from a TMB and immunotherapy (MSKCC) cohort in cBio-
Portal (https://www.cbioportal.org/ accessed on 21 December 2020). Tumor-infiltrating
immune cell profiles across TCGA pan-cancer cohort were downloaded from TIMER (ver-
sion 2.0), a comprehensive resource for systematic analysis of immune infiltrates across di-
verse cancer types (http://timer.comp-genomics.org/ accessed on 21 December 2020) [46].
Immune subtype models (C1–C6) were based on a previous study [48]. The genes con-
tained in each signature were evaluated using model-based clustering by p the “mclust”
R package. Each sample was finally to be grouped based on its predominance with the
C1-C6 signature. Data of mouse brain cells with Yap1 overexpression and Nf2 knockout
were downloaded from GSE48078 [52]. R packages “limma” and “edgeR” were used to
normalize the data and identify the differential gene or protein expression, respectively.
4.5. Gene Signature Scores
4.5.1. YAP-TAZ Target Gene Signature Score
A curated 22-gene YAP-TAZ target gene signature (MYOF, AMOTL2, LATS2, CTGF,
CYR61, ANKRD1, ASAP1, AXL, F3, IGFBP3, CRIM1, FJX1, FOXF2, GADD45A, CCDC80,
NT5E, DOCK5, PTPN14, ARHGEF17, NUAK2, TGFB2, RBMS3) was utilized based on a
previous study [15], which used published RNA-sequencing and ChIP-sequencing data
across various cancer types. YAP-TAZ target score was calculated by summarizing the
Z-normalized log2RSEM (RNA-Seq by Expectation-Maximization) of the expression data
for the 22 curated YAP/TAZ downstream transcription target genes, based on the TCGA
MPM RNA-sequencing data.
4.5.2. Hub Genes-Based Signature Score
Hub genes-based signature score was generated using the top 30 connected genes
(LCK, CD3E, SH2D1A, CD6, CD3D, SIRPG, CD2, SLAMF6, IL2RG, CD247, TBC1D10C,
TRAT1, SIT1, ZAP70, CXCR3, SLA2, ITGAL, CD5, GZMK, TIGIT, CD96, ZNF831, ITK,
THEMIS, PYHIN1, P2RY10, ACAP1, CXCR6, CD27, GPR171) in the red module. The
signature score was calculated by summarizing the Z-normalized log2RSEM of the gene
expression data and then applied to an independent MPM dataset (GSE29354) from NCBI
Gene Expression Omnibus (GEO) data repository portal [49]. R packages “limma” and
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“edgeR” were used to normalize the data and identify the differential gene or protein
expression, respectively [84].
4.6. Survival Analysis
Survival analysis was performed using “survminer” and “survival” R packages.
Tumor samples within the TCGA MPM cohort were divided into two groups, based on
each hub gene’s best-separation cut-off value to plot the Kaplan–Meier survival curves.
4.7. Statistics
Data were presented as mean ± SD, with the indicated sample size (n) representing
biological replicates. Gene expression and survival data derived from the public database,
as well as the correlation coefficient, were analyzed using R (version 3.6.3). p < 0.05 was
considered statistically significant.
5. Conclusions
Overall, our results suggest that NF2 loss-of-function and dysregulated Hippo-YAP
signaling have different molecular aberrations and therapeutic implications in MPM. Based
on these findings, we propose that MPM patients with aberrant Hippo-YAP pathway, e.g.,
determined by IHC staining of clinical MPM samples or genetic alteration of LATS1/2,
may benefit from combined treatment of BCR-ABL-targeted therapies and ICBs, such as
combined Dasatinib and anti-PD-L1 treatment.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13071561/s1, Figure S1: DNA methylation profiles of major genes regulating the Hippo
signaling pathway across TCGA MPM samples. The X-axis represents the methylation probes (450k
array) recognizing different CpG sites of the indicated genes, Figure S2: Functional analysis of genes
enriched in greenyellow and blue modules. A, B, Top 5 significantly enriched Gene Ontology (GO;
biological process [BP]), Kyoto Encyclopedia of Genes and Genomes (KEGG) (B), and Reactome (C)
pathways based on genes in the greenyellow (A) and blue (B) modules. Cnetplot in (A, lower panel)
listed genes in the enriched Reactome pathways, Figure S3: Functional analysis of genes enriched
in turquoise and green modules. A, B, Top 5 significantly enriched Gene Ontology (GO; biological
process (BP)), Kyoto Encyclopedia of Genes and Genomes (KEGG) (B), and Reactome (C) pathways
based on genes in the turquoise (A) and green (B) modules. Cnetplot in (A, lower panel) listed genes
in the enriched Reactome pathways, Figure S4: MPM tumors display the highest correlation pattern
between YAP/TAZ downstream target score and PD-L1 expression. A, Correlation (Spearman)
analysis between the YAP/TAZ downstream target score and PD-L1 expression across the TCGA Pan-
cancer cohort. Of note, MPM tumors display the highest correlation pattern. * indicates a significantly
(p < 0.05) positive correlation; # represents a significantly negative correlation. B, Barplots showing the
YAP/TAZ downstream target score, which reflects the activity of the YAP signaling pathway, across
the TCGA Pan-cancer cohort. Of note, MPM tumors display the highest YAP/TAZ downstream target
score, Figure S5: Immunoblots of MPM cells showing the expression of LATS1, LATS2, and NF2;
Actin as an internal control, Figure S6: Tumor-infiltrating B-cell profiles across the TCGA pan-cancer
cohort based on NF2 and LATS1/2 mutational status. Data were downloaded from TIMER (version
2.0) (See the methods), Figure S7: The interaction map among the common interactors of NF2. Data
were constructed and downloaded from STRING (https://string-db.org/ accessed on 21 December
2020), Table S1: Clinical characteristics of included TCGA MPM patients.
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